EN
HI
Summary
As of 11 Sep, 2026, Venmax Drugs And Pharmaceuticals stock price is ₹15.5. During the trading session, the stock has moved between an intraday low of ₹14.61 and an intraday high of ₹15.80. Over the last 52 weeks, Venmax Drugs And Pharmaceuticals has traded between ₹13.52 and ₹31.49.
The stock has recorded a trading volume of 651 shares,. Its Average Traded Price (ATP) is ₹15.09, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹15.50.
Venmax Drugs And Pharmaceuticals has an upper circuit limit of ₹17.53 and a lower circuit limit of ₹11.69. The total value traded stands at ₹9823.59, and the delivery percentage for the day is 96.29%.
The stock is currently traded with a market lot size of 1. Venmax Drugs And Pharmaceuticals also offers a dividend yield of 0%.
Venmax Drugs And Pharmaceuticals Share Price Chart
Venmax Drugs And Pharmaceuticals Share Key Metrics
Volume
651.00
Market Cap
13.35 CR
LTQ@LTP
1@15.50
ATP
15.09
Var Margin
29.65 %
Circuit Range
11.69-17.53
Delivery %
96.29 %
Value
9823.59
ASM/GSM
No
Market Lot
1
Venmax Drugs And Pharmaceuticals Resistance and Support
Pivot 14.84
Resistance
First Resistance
15.66
Second Resistance
16.71
Third Resistance
17.53
Support
First Support
13.79
Second Support
12.97
Third Support
11.92
Venmax Drugs And Pharmaceuticals Historical Data
| Day | Open | Close | Change(%) | Day High | Day Low |
|---|---|---|---|---|---|
| Fri Sep 11 2026 | 14.98 | 15.5 | 6.16% | 15.8 | 14.61 |
| Thu Sep 10 2026 | 15.89 | 14.6 | 2.60% | 15.89 | 14.02 |
| Wed Sep 09 2026 | 14.98 | 14.23 | -1.11% | 15.39 | 14.03 |
Venmax Drugs And Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-31 | A.G.M. |
| 2026-08-07 | Quarterly Results |
| 2026-05-14 | Audited Results |
| 2026-02-07 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-09-02 | Amalgamation & A.G.M. |
| 2025-08-16 | Others |
| 2025-07-23 | Quarterly Results |
| 2025-05-09 | Audited Results |
| 2025-02-08 | Quarterly Results |
| 2025-01-11 | Preferential issue of shares |
| 2024-11-11 | Quarterly Results |
| 2024-08-12 | Quarterly Results |
Venmax Drugs And Pharmaceuticals News
Venmax Drugs and Pharmaceuticals Ltd - 531015 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Venmax Drugs received NCLT approval for its scheme of amalgamation with Hatri Pharma. The NCLT has directed the company to convene an equity shareholders' meeting on October 24, 2026, to consider the proposed Composite Scheme of Amalgamation. This move is aimed at consolidating pharma businesses and enhancing operational efficiencies.
Sep 08 2026 14:13:15
Venmax Drugs and Pharmaceuticals Ltd - 531015 - Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Venmax Drugs' Board approved Mr. Venkata Rao Sadhanala's redesignation as Managing Director for 5 years, effective March 11, 2026. The Board also regularized Mrs. Padmaja Kalyani Sadhanala and Mr. Revoor Ramachandra as Additional Directors, subject to shareholder approval at the upcoming 37th AGM on September 26, 2026.
Aug 31 2026 17:27:34
Read More
Venmax Drugs And Pharmaceuticals Management
| Name | Position |
|---|---|
| Priyanka Agarwal | Company Secretary & Compliance Officer |
| Venkata Rao Sadhanala | Whole Time Director |
Venmax Drugs And Pharmaceuticals FAQs
The Buying Price of Venmax Drugs And Pharmaceuticals share is 15.5 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Venmax Drugs And Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Venmax Drugs And Pharmaceuticals, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Venmax Drugs And Pharmaceuticals shares is 0. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Venmax Drugs And Pharmaceuticals shares is 0. Useful to assess the stock's value relative to its book value.
To assess Venmax Drugs And Pharmaceuticals’s valuation compare Sector P/E, P/B which are 41.56 & 3.6 with sector averages, along with growth rates and financial metrics.
The Market Cap of Venmax Drugs And Pharmaceuticals is 13.35 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Venmax Drugs And Pharmaceuticals share price is 31.49 & 13.52. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Venmax Drugs And Pharmaceuticals belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year- Auto Square Off Charges
13 Lakh+ Clients
Expert-Backed
Premium Tools
Open Your Free
Demat Account Now!
- AMC For First Year
- Account Opening Fee
- 13 Lakh+ Clients
- Expert-Backed
- Premium Tools
Invest in VENMAX
